Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Blocking of a drug as a treatment for primary progressive multiple sclerosis (PPMS), making it unavailable for use by the UK’s National Health Service (NHS), is being challenged by the country’s MS Society. And it has coupled its opposition with a call to arms – inviting everyone to #SpeakupforMS. Holly, from the society’s campaigns community, … Continue reading Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Ocrevus blocked again, this time for PPMS, as not cost-effective

  So, news came out last week that the UK’s National Health Service will not be providing Ocrevus for treating primary progressive MS (PPMS) in England*. But, panic not, the decision is far from being set in stone. Why is this? Because the decision by the National Institute for Health and Care Excellence, (NICE), was … Continue reading Ocrevus blocked again, this time for PPMS, as not cost-effective

Threat to three DMTs removed after manufacturers cut prices

Manufacturers of three relapsing multiple sclerosis drugs have cut prices to remain available to Britain's National Health Service (NHS). They are all diseases modifying therapies (DMTs). In January, I brought you news that five such drugs were under threat, having been found to be not cost-effective as long-term therapy options. In a draft recommendation from … Continue reading Threat to three DMTs removed after manufacturers cut prices

MS drug Ocrevus could be barred from health service

Ocrevus may have taken the worldwide multiple sclerosis community by storm but it seems set for a rocky ride in the United Kingdom. It’s quite possible that it will not be available through the country’s National Health Service (NHS). Although the drug1, known by the non-brand name, ocrelizumab, was licensed by the European Medicines Agency … Continue reading MS drug Ocrevus could be barred from health service

MS bodies look for NICE support for PPMS treatment

Leading MS organisations are seeking support to gain approval for ocrelizumab (Ocrevus) to treat all primary progressive MS (PPMS). It is already approved for use against early PPMS. Both of the UK’s MS Society and MS Trust are campaigning to get the medication approved for wider use by the country’s National Health Service (NHS). And … Continue reading MS bodies look for NICE support for PPMS treatment

After Long Wait, Zinbryta Gains Approval in Areas of the UK

News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken so long? Possibly, because the first decision, last September, was ‘no.’ The latest decision by … Continue reading After Long Wait, Zinbryta Gains Approval in Areas of the UK